Related Experiment Videos
[Heart failure and vasopeptidase inhibitors]
1Service de cardiologie, hôpital de Hautepierre, avenue Molière, hôpitaux universitaires de Strasbourg, 67098 Strasbourg.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|April 6, 2002
Summary
New drug omapatrilat, a vasopeptidase inhibitor, shows promise in treating cardiac insufficiency by reducing hospital admissions. While not improving exercise tolerance, it offers a potential new therapeutic avenue for heart failure patients.
Area of Science:
- Cardiovascular Pharmacology
- Drug Discovery
Context:
- Cardiac insufficiency (heart failure) presents significant morbidity and mortality.
- Developing novel therapeutic agents is crucial for managing heart failure progression.
Purpose:
- To evaluate the efficacy of omapatrilat, a vasopeptidase inhibitor, in patients with cardiac insufficiency.
- To assess omapatrilat's impact on exercise tolerance and clinical outcomes compared to existing treatments.
Summary:
- Omapatrilat simultaneously inhibits neutral endopeptidase and angiotensin-converting enzyme, potentiating natriuretic peptides and bradykinin while blocking angiotensin II formation.
- The IMPRESS study found no significant difference in exercise tolerance between omapatrilat and lisinopril.
- Omapatrilat demonstrated significantly greater effectiveness than lisinopril in reducing the combined endpoint of death and hospital admission for cardiac insufficiency.
Impact:
- Omapatrilat shows potential for improving clinical outcomes in heart failure, specifically reducing hospitalizations.
- Ongoing studies like OVERTURE will further elucidate omapatrilat's role in managing heart failure.
- The development of dual-acting vasopeptidases represents a rational approach to modulating key neurohormonal systems in cardiovascular disease.